Antibe Therapeutics has designed and developed novel anti-inflammatory drugs that represent a significant advance on presently available drugs of this class. We have exploited the powerful properties of hydrogen sulfide, an endogenous gaseous mediator, to dramatically improve the safety of nonsteroidal anti-inflammatory drugs (NSAIDs). A strong intellectual property portfolio is in place.
Based in Toronto, Antibe Therapeutics has researchers and partners in the US, the UK, China, Italy and Brazil. Antibe is financed by founders and private investors.